Vir Biotechnology (NASDAQ: VIR) — Perfil da empresa, notícias e dados financeiros
Vir Biotechnology develops treatments for infectious diseases like hepatitis B and COVID-19 using cutting-edge technologies.
Vir Biotechnology
Vir Biotechnology (NASDAQ:VIR) is deeply invested in the research and development of treatments and therapies for serious infectious diseases such as hepatitis B, influenza A, and COVID-19, leveraging cutting-edge technologies to address global health challenges. Traded on the NASDAQ under the ticker symbol VIR, this bio-tech firm focuses on using immune programming to develop solutions for conditions that currently lack adequate treatments. With a commitment to improving patient outcomes, Vir's projects range from early to late-stage clinical trials, aiming not just to treat diseases but to fundamentally understand and manipulate the immune system's response to pathogens. Their objective is to lead the way in infectious disease treatment, pioneering future standards in therapeutics and preventative care.
Resumo
Operações
Produtos e/ou serviços de Vir Biotechnology
- Development and commercialization of therapies for the treatment of COVID-19, prioritizing a monoclonal antibody treatment designed to neutralize the virus.
- Research on hepatitis B virus (HBV) treatments, focusing on functional cure strategies through a combination of therapeutic approaches.
- Influenza treatments, including the development of monoclonal antibodies aimed at providing a functional cure or significant protection against flu viruses.
- HIV cure projects, focusing on the development of broadly neutralizing antibodies aiming to contribute to cure strategies for HIV/AIDS.
- Respiratory syncytial virus (RSV) treatment efforts, dedicated to creating monoclonal antibodies for the prevention and treatment of RSV infections.
- Investment in novel platform technologies for identifying and developing antibodies against pathogens with pandemic potential, aiming to rapidly respond to emerging infectious diseases.
equipe executiva do Vir Biotechnology
- Marianne De BackerPresident, CEO & Director
- Vanina de VerneuilExecutive VP, General Counsel & Corporate Secretary
- Lawrence CoreyCo-Founder & Scientific Advisor
- Louis J. PickerCo-Founder & Scientific Advisor
- Aziz SawafExecutive VP, CFO & Principal Financial Officer
- Brent SabatiniSenior VP, Principal Accounting Officer & Chief Accounting Officer
- Maninder HoraExecutive VP & Chief Technical Operations Officer
- Jennifer Eileen TowneExecutive VP & Chief Scientific Officer
- Kiki PatelHead of Investor Relations
- Carolyn WangSenior Vice President of Corporate Communications
Principais indicadores financeiros
Resultados divulgados pela Vir Biotechnology, em USD.
- Cap. de mercado
- 2 bi
- Receita (TTM)
- 303,2 mi
- P/L
- —
- LPA (diluído, TTM)
- -1.8
- Dividend yield
- —
- Margem de lucro
- -83.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 68,6 mi | -468 mi | -438 mi | |
| 74,2 mi | -523,4 mi | -522 mi | |
| 86,2 mi | -661 mi | -615,1 mi | |
| 1,6 bi | 833,1 mi | 515,8 mi |